Products and Platforms
Knopp is advancing dexpramipexole as an immunological therapeutic based on its preclinical and clinical activity in modulating white blood cells known as eosinophils.
Knopp is advancing dexpramipexole as a novel, oral investigational treatment for amyotrophic lateral sclerosis (ALS). ALS is a devastating disease of progressive paralysis with very limited treatment options.
The disruption of cellular bioenergetics has emerged as a common factor in pathways leading to cell death in ALS, Parkinson's, and other neurodegenerative disorders. Knopp is discovering novel small-molecule mediators of these pathways.
Ion channels, or proteins that regulate the excitability of cells, represent an important class of drug targets in several neurological and cardiovascular conditions. Knopp is discovering novel compounds to modulate these channels.
- KNOPP BIOSCIENCES AND NIH TO COLLABORATE IN EVALUATING DEXPRAMIPEXOLE IN PATIENTS WITH HYPEREOSINOPHILIC SYNDROME January 8, 2014
- PRIZE4LIFE AND KNOPP NEUROSCIENCES ANNOUNCE DONATION OF EMPOWER PHASE 3 DATA TO PRO-ACT DATABASE June 13, 2013
- Biogen Idec reports top-line results from Phase 3 trial investigating dexpramipexole in people with amyotrophic lateral sclerosis (ALS) January 3, 2013